BioNTech is dismantling the manufacturing network it built during the pandemic, a retreat that will cost roughly 1,800 jobs across three German sites and formally close the chapter on its years as a mass vaccine producer. The Mainz-based biotech confirmed on Monday that its plants in Marburg, Idar-Oberstein and Tübingen will shut down after efforts to find buyers fell through.
The wind-down will be staggered. Tübingen is slated to close by the end of 2027, Marburg follows in early 2028, and Idar-Oberstein is set to be fully unwound by the end of 2028. Management is shedding capacity it no longer needs in order to funnel resources toward cancer therapies, a pivot that asks shareholders to weigh near-term disruption against the promise of a leaner, research-driven company.
A Founder Sale, Executed by the Playbook
The restructuring has coincided with signals from the top. Co-founder Uğur Şahin sold 66,000 shares on Wednesday through a pre-arranged trading plan set up under Rule 10b5-1, a structure common in US markets that automates disposals regardless of day-to-day market moves. A mandatory disclosure put his remaining holding at 39,432,320 shares.
That residual stake matters more than the sale itself. Even after the transaction, Şahin retains a stake of more than 39.4 million shares, a level of personal commitment that market participants read as continued alignment between the company’s scientific leadership and its long-term direction. The trading plan itself dates back to June 3, 2026.
Clinical Data Carry the Valuation Case
What ultimately determines BioNTech’s worth is not its factory footprint but the maturity of its oncology pipeline. Roughly two weeks ago, the company and its partner OncoC4 released updated results from the Phase 3 PRESERVE-003 trial of gotistobart in previously treated squamous non-small cell lung cancer. Among 87 randomized patients, median overall survival reached 18.5 months, against 10.0 months for those on the chemotherapy agent docetaxel.
That gap underpins the scientific case for the approach, and the pivotal second stage of the study is now underway. Should it confirm the earlier findings, gotistobart could become a cornerstone in the lung cancer segment and give BioNTech an independent foothold in the global oncology market. The company’s market capitalization of EUR 21.57 billion reflects an expectation that new revenue streams will emerge over the medium term; simply cutting capacity will not be enough to cement investor confidence.
Should investors sell immediately? Or is it worth buying BioNTech?
Legal and Operational Overhangs
Not everything on the agenda is within the company’s control. A US federal judge rejected motions by BioNTech, Pfizer and Moderna to dismiss patent claims brought by Bayer’s Monsanto unit over the mRNA technology used in COVID-19 vaccines, as Reuters reported. The interim ruling did not establish any infringement.
Closer to home, a fire in a laboratory exhaust system at the Mainz site in mid-September triggered an emergency response, with three people taken to hospital as a precaution. The blaze was extinguished quickly, but the incident highlights the operational risks that come with running an active research operation.
Attention has also drifted toward the founders’ activities beyond the core business. The Mainz city government recently welcomed the establishment of Arife SE in the city by Şahin and Özlem Türeci. While the venture is not a BioNTech project, investors are watching for any split in leadership focus.
Chart Levels and the Road Ahead
On the technical side, the stock closed Friday at EUR 86.10, a gain of 5.8% since the start of the year, and sits just above its 200-day moving average of EUR 84.58. Holding that level would keep the stabilization scenario intact; a sustained break below it could prompt a reassessment of the risks tied to the plant overhaul.
Two dates now anchor the calendar. The next decisive milestone is the progress of the pivotal second phase of the gotistobart trial, which will determine the commercial validation of the program. On the governance front, the supervisory board proposed KPMG AG Wirtschaftsprüfungsgesellschaft as auditor for fiscal 2027 about two weeks ago, with the final decision resting with the upcoming annual general meeting.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from October 3 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 3.
BioNTech: Buy or sell? Read more here...
